Molecular Devices Introduces Fatty Acid Uptake Assay to Target Metabolic Diseases
12 January 2005 - 8:30AM
PR Newswire (US)
Molecular Devices Introduces Fatty Acid Uptake Assay to Target
Metabolic Diseases SUNNYVALE, Calif., Jan. 11
/PRNewswire-FirstCall/ -- Molecular Devices Corporation
(NASDAQ:MDCC) today announced the launch of its QBT(TM) Fatty Acid
Uptake Assay Kit, the first assay kit that addresses the need for a
single-step, homogenous in vitro assay for fatty acid uptake for
use in high- throughput screening and metabolic disease research.
Defects in fatty acid metabolism have been linked to several
pathological states, including insulin desensitization, Type 2
diabetes, obesity and cardiovascular disease. The development of
fatty acid uptake regulators as potential drugs is dependent upon
having a rapid assay that can be used in high-throughput screening.
Conventional assays using radioisotopes are expensive and
time-consuming and have limited the ability of drug researchers to
identify potential new drugs via high-throughput screening. The QBT
Fatty Acid Uptake Assay removes these limitations by providing a
rapid, reproducible, inexpensive method for laboratory screening.
Susan Williams-Clark, Director of Marketing at Molecular Devices
stated, "Working together with researchers at the Palo Alto Medical
Foundation's Research Division, we have applied our proprietary
quench technology to develop the first single-step homogenous assay
for fatty acid uptake. Since this assay uses a fluorescence-based
readout rather than a radioactivity-based one, it eliminates the
safety risks associated with conventional radiolabel assays, in
addition to being faster and easier to perform." Williams-Clark
continued, "Prior to the development of this assay, it was
extremely difficult for drug discovery researchers to study fatty
acid uptake processes and identify new regulators. We believe that
the QBT Fatty Acid Uptake Assay Kit will enable high-throughput
screening of these drug targets and enhance fatty acid metabolism
research." Similar to Molecular Devices' FLIPR Assay Kits, the QBT
Fatty Acid Uptake Assay eliminates the need for cell washing steps,
resulting in a faster, more streamlined route to drug discovery.
Molecular Devices Corporation is a leading supplier of
high-performance bioanalytical measurement systems that accelerate
and improve drug discovery and other life sciences research. The
Company's systems and consumables enable pharmaceutical and
biotechnology companies to leverage advances in genomics,
proteomics and combinatorial chemistry by facilitating the high-
throughput and cost-effective identification and evaluation of drug
candidates. The Company's solutions are based on its advanced core
technologies that integrate its expertise in engineering, molecular
and cell biology and chemistry. Molecular Devices enables its
customers to improve research productivity and effectiveness, which
ultimately accelerates the complex process of discovering and
developing new drugs. This press release contains "forward-looking"
statements, including statements related to the prospects for or
potential customer use of the QBT(TM) Fatty Acid Uptake Assay Kit.
Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements. Words such as "believes," "anticipates," "plans,"
"expects," "will," and similar expressions are intended to identify
forward- looking statements. There are a number of important
factors that could cause the results of Molecular Devices
Corporation to differ materially from those indicated by these
forward-looking statements, including, among others, risks related
to the development of new products and other risks detailed from
time to time in the Company's SEC reports, including its Annual
Report on Form 10-K for the year ended December 31, 2003, as
amended, and its Quarterly Report on Form 10-Q for the quarter
ended September 30, 2004. Molecular Devices Corporation does not
undertake any obligation to update forward-looking statements.
DATASOURCE: Molecular Devices Corporation CONTACT: Tim Harkness of
Molecular Devices Corporation, +1-408-747-3533 Web site:
http://www.moleculardevices.com/
Copyright
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Molecular Devices (MM) (NASDAQ): 0 recent articles
More Molecular Devices (MM) News Articles